Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: A cancer and leukemia group B study

Journal of Clinical Oncology

Volumn 14, Issue 5, 1996, Pages 1589-1598

  Perloff, M ^a   Norton, L ^a   Korzun, A H ^a   Wood, W C ^a   Carey, R W ^a   Gottlieb, A ^a   Aust, J C ^a   Bank, A ^a   Silver, R T ^a   Saleh, F ^a   Canellos, G P ^a   Perry, M C ^a   Weiss, R B ^a   Holland, J F ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOXYMESTERONE; METHOTREXATE; PREDNISONE; THIOTEPA; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ALOPECIA; AMENORRHEA; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; CROSSOVER PROCEDURE; DOSE RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PERIPHERAL NEUROPATHY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 9244264421     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.5.1589     Document Type: Article

References (30)

1. Early Breast Cancer Trialists' Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 319:1681-1692, 1988
2. Kardinal CG, Perry MC, Korzun AH, et al: Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy. A subset analysis of CALGB study 8081. Cancer 61:415-419, 1988
3. Skipper HE: Laboratory models: Some historical perspectives. Cancer Treat Rep 70:3-7, 1986
4. Frei E III, Canellos GP. Dose: A critical factor in cancer chemotherapy. Am J Med 69:585-593, 1980
5. Cooper RG, Holland JF, Glidewell O: Adjuvant chemotherapy of breast cancer. Cancer 44:793-798, 1979
6. Bonadonna G, Valagussa P, Rossi A, et al: Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 5:95-115, 1985
7. Tormey DC, Weinberg VE, Holland JF, et al: Randomized trial of five- and three-drug chemotherapy and chemoimmunotherapy in women with operative node-positive breast cancer. J Clin Oncol 1:138-145, 1983
8. Bonadonna G, Valagussa P: Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10-15, 1981
9. Howell A, Bush H, George WD, et al: A controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate and fluorouracil for breast cancer. Lancet 2:307-311, 1984
10. Perloff M, Norton L, Korzun A, et al: Advantage of an Adriamycin (A) combination plus Halotestin (H) after initial cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone (CMFVP) for adjuvant therapy of node-positive stage II breast cancer. Proc Am Soc Clin Oncol 5:70, 1986 (abstr)
11. Tormey DC, Weinberg VE, Leone LA, et al: A comparison of intermittent versus continuous and of Adriamycin versus methotrexate five drug chemotherapy for advanced breast cancer. A Cancer Leukemia Group B study. Am J Clin Oncol 7:231-239, 1984
12. Hart RD, Perloff M, Holland JF: One day VATH (vincristine. Adriamycin, thiotepa, and Halotestin) for advanced breast cancer refractory to prior chemotherapy. Cancer 48:1522-1527, 1981
13. Perloff M, Hart RD, Holland JF: Vincristine, Adriamycin, thiotepa and Halotestin (VATH). Therapy for advanced breast cancer refractory to prior chemotherapy. Cancer 42:2534-2537, 1978
14. Norton L, Simon R: Tumor size, sensitivity to therapy and the design of treatment protocols. Cancer Treat Rep 61:1307-1317, 1977
15. Norton L: Implications of kinetic heterogeneity in clinical oncology. Semin Oncol 12:231-238, 1985
16. Sheehe PR, Bross IDJ: Latin square to balance immediate residual and other order effects. Biometrics 17:405, 1961
17. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-202, 1972.
18. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc A 135:185-198, 1972
19. Snedecor GW, Cochran WG: Statistical Methods (ed 7), Chapter 7. Ames, IA, Iowa State University, 1980
20. Snedecor GW, Cochran WG: Statistical Methods (ed 7), Chapter 8. Ames, IA, Iowa State University, 1980
21. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
22. Hryniuk WM, Levine MN, Levin L: Analysis of dose intensity in early (stage II) and advanced breast cancer. NCI Monogr 1:87-94, 1986
23. Korzun A, Norton L, Perloff M, et al: Clinical equivalence despite dosage differences of two schedules of cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone (CMFVP) and of adjuvant therapy of node positive stage II breast cancer. Proc Am Soc Clin Oncol 7:12, 1988 (abstr)
24. Henderson IC, Gelman RS, Harris JR, et al: Duration of therapy in adjuvant chemotherapy trials. NCI Monogr 1:95-98, 1986
25. Levine MN, Gent M, Hryniuk W, et al: A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer. J Clin Oncol 8:1217-1225, 1990
26. Norton L: A Gompertzian model of human breast cancer growth. Cancer Res 48:7067-7071, 1988
27. Nowell PC: The clonal evolution of tumor cell populations. Science 194:23-28, 1976
28. Fisher B, Fisher ER, Redmond C: Ten-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine mustart (L-PAM) in the management of primary breast cancer. J Clin Oncol 4:929-941, 1986
29. Goldie JM, Coldman AJ: A mathematical model for relating the drug sensitivities of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727-1733, 1979
30. Bonadonna G, Zambetti M, Valagussa P: Sequential versus alternating adjuvant chemotherapy with adriamycin (ADM) and CMF: Ten-year results in breast cancer with > 3 positive nodes. Proc Am Soc Clin Oncol 14:118, 1995 (abstr)